Orthobiologics Market Overview and Introduction

Orthobiologics Market was valued at over US$ 5.5 Bn. in 2017. It is anticipated to grow at a CAGR of 5.2% from 2019 to 2030.

Orthobiologics products are widely used during orthopedic surgery that facilitates quick healing. Various biological substances are used in Orthobiologics that help musculoskeletal injuries to heal faster. Orthobiologics play and important role in healing of tendon, ligament, bone formation cartilage regeneration and other orthopedic related injuries. Researchers are now focusing on stem cells and regenerative medicine to cure arthritis and orthopedic related disorders.

The global market is driven by technological advancements in the regenerative medicine and stem cell therapy arena, increasing number of sports related injuries and road accident, rising prevalence of spine related surgeries, and high incidence of musculoskeletal disorders are major factors driving the market. However, high cost related to orthobiologics products and surgeries is likely to restrain the market to certain extent.

Orthobiologics Market by Product

On the basis of product, this market is segmented into bone morphogenetic proteins, allografts, viscosupplementation, demineralized bone matrix (DBM), stem cell therapy, and other products. The stem cell therapy and allograft segment is estimated to grow at fastest growth rate in the global market. Growth of this segment can be attributed to increasing focus of companies to innovative advanced stem cell therapy and increasing number of sports related injuries are expected to drive the growth of the market.

Orthobiologics Market by Application

Based on the key applications of orthobiologics, the market is segmented into soft tissue injuries, reconstructive surgery, trauma, and spinal fusion. The reconstructive surgery segment is estimated to account for the largest share of this market. The large share of this segment can be attributed to the geriatric population facing arthritis problem and rinsing number of musculoskeletal procedures are likely to drive the growth of the segment.

Orthobiologics Market by End-Users

On the basis of end user, the orthobiologics market is segmented into hospitals and clinics, ambulatory care settings & orthopedic clinics. The hospitals and clinics segment is estimated to account for the largest share of the orthobiologics market. Increasing number of sports related injuries, stem cell and allograft treatment leading to faster recovery after surgery are some of the factors driving the growth of end-user segment.

Orthobiologics Market by Regions

The global orthobiologics market can be segmented into North America, Europe, Asia Pacific, and Rest of World (ROW). North America dominated the market of orthobiologics, followed by Europe and Asia Pacific. North America will continue to dominate the global market in the forecast period owing to factors such as growing need of orthobiologics products and highly developed healthcare system and presence of advance therapy for orthopedic treatment. However, Asia Pacific is expected to witness the highest CAGR, with the growth in this market centered at China, India, and Japan. Factors such as the rising focus of major players in emerging Asian countries and government support are driving the growth of the orthobiologics market in this region. The high cost of orthobiologics products and reimbursement policies & regulation related to Orthobiologics products may restrain market growth to a certain extent.

Orthobiologics Market Prominent Players

The prominent players in the global orthobiologics market are Medtronic, DePuy Synthes, Zimmer Biomet, MTF, Sanofi, Bioventus, Arthrex, Seikagaku and NuVasive among others.